



3rd Health Programme 2014-2020

Grants for Actions co-financed with Member State authorities 2016

Giovanni Nicoletti
National Focal Point - Italia

Roma, Consumers,
Health And Food
Executive Agency 16 marzo 2016

Call 2016: Actions co-financed with MS authorities – Joint Actions

- JA have a clear EU added value and are co-financed either by competent authorities that are responsible for health in the MS or in the third countries participating in the Programme, or by public sector bodies and non-governmental bodies mandated by those competent authorities.
- *Proposals should provide a genuine European dimension. Depending on the scope of the action, previous JA involved on average 25 partners.*
- A multibeneficiary grant agreement.

3rd HP: New procedure for JA

- Direct grant procedure = > all participants have to be nominated first (no open call!)
- If an European umbrella organisation/NGO wants to participate in a JA, it must be designated by a MS competent authority through a transparent procedure.
- As in PHP2, international organisations (e.g. WHO, OECD, etc.) are not eligible to participate.
- Chafea will carry out spot checks concerning the transparency and legality of the designation process.

How much co-funding?

- *EU contribution is **60 %** of the total eligible cost;*
- *In cases of exceptional utility, it is **80 %**.*

Who can participate?

- *Country eligibility – EU28 and EEA (Norway and Iceland) + Serbia*
- *Focus: MS authorities*
- *Public sector bodies and non-governmental bodies from the above countries can participate in JA, if they are mandated by competent authorities.*

Exceptional utility criteria

1. At least 30 % of the budget of the proposed action is allocated to MS whose gross national income (GNI) per inhabitant is less than 90 % of the Union average.

This criterion intends to promote the participation from MS with a low GNI.

2. Bodies from at least 14 participating countries participate in the action, out of which at least four are countries whose GNI per inhabitant is less than 90 % of the Union average.

This criterion promotes wide geographical coverage and the participation of MS authorities from countries with a low GNI.



European
Commission

Joint Actions in the WP 2016

Budget 13,8 million for:

- JA-01-2016 - *Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention and linkage to care* (€ 2 000 000 EU co-funding)
- JA-02-2016 - *Action on chronic diseases* (€ 5 000 000 EU co-funding)
- JA-03-2016 - *Tobacco control* (€ 2 000 000 EU co-funding)
- JA-04-2016 - *Antimicrobial resistance and Health Care Associated Infections*(€ 4 000 000 EU co-funding)
- JA-05-2016 - *Authorisation of preparation processes in blood and tissues and cells* (€ 800 000 EU co-funding)



JOINT ACTIONS 2016 – thematic priority 1

TITLE *Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention and linkage to care*

OBJECTIVES

- This action will build upon the results obtained by the Improving Quality in HIV Prevention – 'Quality Action' initiative (co-financed as a joint action under the health programme¹⁹). In particular, it will take into account the 'Charter for Quality in HIV Prevention' with the main objectives: 1) to ensure that the cross-border aspect of HIV/AIDS, STI, Hepatitis and tuberculosis is considered when planning national strategies; 2) to develop behavioural approach to testing and prevention activities and possible links with the Horizon 2020 longer-term research objectives; 3) to use the available materials developed by EU-level technical expertise from several agencies for direct country support and capacity building (e.g. ECDC and EMCDDA) specifically targeted to vulnerable groups for all the diseases mentioned before; and 4) to provide a platform – linked with the EU HIV/AIDS Think Tank and the Civil Society Forum – for exchange of best practice and discussions on innovations, on innovative issues such as self-testing, pre-exposure prophylaxis for HIV and other additional challenging emerging issues. The action will gear up the operational phase of the 'Charter' on the basis of agreed quality principles and criteria and will extend the coverage to sexually transmitted diseases, hepatitis and tuberculosis prevention, testing and care.

DELIVERABLES

- Expected to include innovative tools and information packages based on new achievements in the areas of prevention, testing and linkage to treatment. It is expected to promote high quality prevention and to strengthen the essential links between prevention strategies, testing and treatments and will address the needs of the most affected and vulnerable groups as cited above. This work will include specific activities to involve stakeholders

AMOUNT: 2 000 000 EUR

JOINT ACTIONS 2016 – thematic priority 2

TITLE *Action on chronic diseases*

OBJECTIVES

- This action co-financed with Member State authorities will select and finance activities that help to identify efficient means to reduce the burden of chronic diseases, increase the sustainability of health systems and develop human capital. The focus will be on tangible activities with a potential to trigger health and chronic disease policies in Member States with a potential to improve health outcomes. This action will support Member States in developing and refining national plans and strategies to address chronic diseases and will facilitate and intensify the exchange of good practices and knowledge with regard to the prevention and management of chronic diseases

ACTIVITIES

- Along the priorities identified for taking action on chronic diseases this joint action will contribute to the identification and development of pilot actions in response to the chronic diseases challenge with a focus on the following areas: (i) integrated approaches in screening and early detection of preventable diseases; (ii) integrated approaches to address the main common risks factors (smoking, alcohol abuse, unhealthy diet, physical inactivity and others) as to strengthen prevention across health and social care services; (iii) approaches to overcome health system silos towards a better integration of prevention and health care; (iv) approaches to address multi-morbidity and polypharmacy effectively through evidence-based interventions; (v) identification of essential elements for national chronic disease strategies, including communication elements (21); (vi) means to reduce avoidable costs and increase efficiency of health care system management; and (vii) the timely integration of research findings for prevention and management of chronic diseases. This work will involve stakeholders.

AMOUNT: 5 000 000 EUR



JOINT ACTIONS 2016 – thematic priority 3

TITLE *Tobacco control*

OBJECTIVES AND ACTIVITIES

- Regulatory capacities vary considerably between Member States. Effective mobilisation of the limited resources available at both national and EU level can generate significant synergies, in particular for peer review and assessment of comprehensive studies on priority additives.
- The activities should also include an assessment of data on ingredients in tobacco products submitted for the first time under the new reporting format in 2016 and building up of appropriate laboratory capacity to verify the submitted data and support the enforcement. The data assessment can subsequently lead to further improvement of the submission platform to further enhance comparability of the submitted data.
- Data submitted shall also serve the purpose of supporting regulatory decisions on tobacco ingredients in line with Article 7 of the TPD.
- At the same time regulators will receive notifications of all e-cigarettes currently available in the EU, and will begin to receive prior notification of e-cigarettes still to be launched.
- This action should also provide for efficient work-sharing in this area, including on assessment and verification of the notified data, which will contribute to enforcement and lead to further improvement of the submission platform and enhancement of comparability of the submitted data on e-cigarettes. The issue of comparability of submitted data in areas where testing methods have not yet been standardised/agreed, such as the measurement of e-cigarette emissions, should also be addressed.
- This work will include specific activities with regard to dissemination and networking

AMOUNT: 2 000 000 EUR



JOINT ACTIONS 2016 – thematic priority 4

TITLE *Antimicrobial resistance and Health Care Associated Infections*

OBJECTIVES

- This action will specifically aim to: (i) support the development of national strategies and action plans on antimicrobial resistance; (ii) support strategy development at national, local, and health care setting level (hospital, long term care, community) in the field of health-care associated infections, including optimising the implementation at national level of work done by the ECDC; (iii) develop and enhance the implementation of evidence-based tools, including those prepared by the ECDC and through training, organisational change and/or other methods to enable sustainable improvements in practice by health care staff and teams in hospitals, as well as in long term care and community settings; (iv) strengthen the 'one health' approach and coordination with relevant sectors – including for AMR with animal health, food safety, agriculture, environmental and research and the Joint Programming Initiative (JPI) on AMR ; (v) contribute to the implementation of relevant research findings and identify priorities for research; and (vii) promote awareness and commitment by governments and stakeholders.

ACTIVITIES

- This action will be taken forward in close collaboration with ECDC and other Commission services involved in the 'one health' approach to responds to the threats of AMR and HCAI. It will include the following actions: (i) exchange of information and good practice in relation to strategy development and implementation of actions to address AMR and HCAI, including the involvement of national focal points; (ii) activities to promote the 'one health' approach and foster inter-sectoral action; (iii) state of the art reviews and development of tools, guidelines and training for supporting and maintaining good practice in clinical care in relation to AMR and HCAI in the hospital, long term care and community settings; (iv) consultation and development of activities to support the implementation of EU policy on AMR and HCAI; (v) activities linking research results to policy, and contributing to the research agenda from a policy perspective; (vi) activities to promote awareness and involvement of stakeholders in dissemination and networking, including a final conference; and (vii) other relevant activities on AMR and HCAI.

AMOUNT: 4 000 000 EUR



JOINT ACTIONS 2016 – thematic priority 5

TITLE *Authorisation of preparation processes in blood and tissues and cells*

OBJECTIVES

- Blood and tissue establishments are subject to continuous medical progress and innovation. Each of these innovations brings changes in the operational set-up of the processes in the establishments, calling for assessment and authorisation by the competent authorities. In addition, such changes might lead to changes in the clinical outcomes for patients who benefit from transfusion or transplantation.
- Such authorisations therefore require access to specific technical knowledge and clinical expertise. These are not always immediately available in each of the national and regional competent authorities in the EU 28 Member States. This action aims to bring together this combination of skills from different EU Member States to facilitate the development of a common and optimal approach to assess and authorise innovative preparation processes in blood and tissue establishments.
- The results should include a manual and training for competent authorities on the assessment and authorisation of new or modified preparation processes.

ACTIVITIES

- This action co-financed with Member State authorities should help national authorities with their assessments and authorisations by: (i) identifying groups of innovative processes and their risks and benefits, as well as the need for assessment before authorisation, mainly in terms of safety, quality and clinical outcome; (ii) mapping and assess existing national procedures and resources (e.g. centres/sources of different expertise consulted by competent authorities) to assess and authorise (innovative) processes in tissue and blood establishments; (iii) developing common guidance for the assessment and authorisation of preparation processes in the blood and tissue and cell sectors, with a particular focus on cross-border exchange of data and expertise, including potential joint assessments; and (iv) preparing a manual and organising training courses, to disseminate the agreed optimal approach.
- This action should take into consideration other EU-funded actions in the area of substances of human origin.

AMOUNT: 800 000 EUR

The Role of the MS

- MS to nominate participants prior to Chafea invitation to prepare the proposal



Participants

- **Competent authorities** (national or regional level) or other **bodies** (public sector body/NGO: nominated via a transparent procedure, according to relevant national legislation) to *participate in one or more of the listed JA*

Body other than a competent authority to participate:

- The designation must be done through a **transparent procedure** and according to its relevant national legislation.
- Article 190(1)(d) of the Rules of Application of the Financial Regulation, the Member State/EEA is fully responsible to put in place the designation procedure and ensure that the requirements of transparency and legality are respected.
- **Third Health Programme (Articles 7 and 8)** public sector bodies, in particular **research and health institutions, universities and higher education establishments** as well as **non-governmental bodies** can be mandated to participate in the joint action on behalf of the Member State/EEA country.

- Prevedere in prima ipotesi la partecipazione diretta alle Azioni (in via esclusiva o concorrente) da parte del Ministero
- In difetto, procedere alla identificazione degli Enti esterni esclusivamente nell' ambito della rete di collaborazioni istituzionali del Ministero (ISS, IRCCS, IZS, Regioni)
- Selezionare Enti che, vuoi per disposizione diretta di leggi, per abituale collaborazione o supporto alle attività tecniche ministeriali, ovvero avendo svolto attività di leadership nazionale di progetti italiani ed europei, si possano considerare, nei singoli settori, pienamente rappresentativi del Paese sia in termini di requisiti tecnici che di ruolo strategico
- Per le Regioni, procedere per consenso/designazione Commissione Salute



European
Commission

Letter to the Permanent Representatives

■ Ref. Ares(2016)1116092 - 04/03/2016



EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
Public health
Director

Luxembourg,
sante.ddg1.c.1IK/Lo(2016)1226451

NOTE FOR THE ATTENTION OF PERMANENT REPRESENTATION IN THE EU

Your Excellency,

Subject: Health Programme in 2016 – Implementation of actions co-financed with Member State health authorities (*commonly referred to as 'joint actions'*)

I am writing to you regarding the joint actions planned for 2016 under the third EU Health Programme 2014-2020. The work programme was adopted on 1 March 2016. It foresees approximately € 13,8 million for the following actions co-financed with Member State authorities :

- JA-01-2016 . Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention and linkage to care (€2 million EU co-funding)
- JA-02-2016 Action on chronic diseases (€5 million EU co-funding)
- JA-03-2016 Tobacco control (€ 2 million EU co-funding)
- JA-04-2016 Antimicrobial resistance and Health Care Associated Infections (€4 million EU co-funding)
- JA-05-2016 Authorisation of preparation processes in blood and tissues and cells (€800 000 EU co-funding)



European

OFFICIAL NOTIFICATION
of participation as a partner in a Joint Action

I, Ms/Mr

name (Title/Function)

duly authorised to sign this notification on behalf of the

*name of the ministry/
governmental organisation*

officially notify the Consumer, Health, Agriculture and Food Executive Agency that the
*organization official name
and (acronym)*

legally represented by:

name of legal representative

is an eligible

- Competent Authority
 Another body

to participate on behalf of
country/regional entity

and under its responsibility in the following joint action to be funded under the Health Programme 2016:

- JA-01-2016: Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention
 JA-02-2016: Action on chronic diseases
 JA-03-2016: Tobacco control
 JA-04-2016: Antimicrobial resistance and Health Care Associated Infections
 JA-05-2016: Authorisation of preparation processes in blood and tissues and cells

Date and Place

Name and Signature




Consumer,
Health And Food
Executive Agency

QUANDO ?



Deadline presentazione candidature al Ministero della salute

2 giugno 2016



**Deadline for NOMINATION by the
competent authority**

June 16., 2016

DOVE ?



Le candidature vanno indirizzate al
Ministero della salute
DG della prevenzione sanitaria
Viale Giorgio Ribotta 5
00144 – Roma

Una copia elettronica della richiesta
va indirizzata a:

dgprev@postacert.sanita.it


e a

nfp_eahc@sanita.it



European
Commission

Next steps





Electronic submission !upon invitation!

- Electronic Submission System used for H2020 and other programmes
- No paper / online submission!
- Information will be on Chafea, SANCO web and the Participant Portal
- Evaluation & grant agreement: online

Evaluation = Quality assurance

- Not subject to competition!
- Direct grant procedure!
- Subject to a negotiation process !



European
Commission



Commissione
europea

http://ec.europa.eu/chafea/documents/health/leaflet/chafea-joint-action-2015_en.pdf



European
Commission

EU support for key public health initiatives
2008-2013

JOINT
ACTIONS

Consumers, Health
Agriculture and Food
Executive Agency

FINANZIAMENTI NELL'AMBITO DEL TERZO PROGRAMMA IN MATERIA DI SALUTE 2014-2020



*Azioni cofinanziate da autorità
degli stati membri
(Azioni Congiunte)*

Il programma riguarda la promozione della salute in Europa, incoraggiando la cooperazione tra gli Stati membri per migliorare le politiche sanitarie a vantaggio dei cittadini, e mira a sostenere e integrare le iniziative sanitarie messe in atto dagli Stati membri.

Il programma si traduce in programmi di lavoro annuali che definiscono le azioni da intraprendere nei settori prioritari stabiliti nel regolamento (UE) n. 282/2014. Su questa base, ogni anno l'Agenzia esecutiva per i consumatori, la salute e la sicurezza alimentare organizza un invito a presentare proposte.

Le azioni congiunte sono uno strumento di finanziamento previsto dal terzo programma dell'Unione in materia di salute 2014-2020.

CHE COS'È UN'AZIONE CONGIUNTA?

Le azioni congiunte hanno un evidente valore aggiunto a livello di Unione europea e sono cofinanziate da autorità competenti responsabili per la sanità negli Stati membri o nei paesi terzi che aderiscono al programma, oppure da enti del settore pubblico e organismi non governativi su incarico delle suddette autorità competenti.

Per risultare significative da un punto di vista sia tecnico sia politico, le proposte di azioni congiunte devono avere una vera **dimensione europea**. A seconda della loro portata, le azioni congiunte precedenti hanno coinvolto in media 25 partner.

CHI PUÒ PARTECIPARE?

Ammissibilità di un paese

Per beneficiare di una sovvenzione dell'UE per un'azione congiunta, l'autorità competente deve avere sede legale:

- nell'Unione europea (in uno qualsiasi dei 28 Stati membri) oppure
- in un paese dell'EFTA aderente all'accordo sullo Spazio economico europeo che abbia confermato la propria partecipazione al programma.

Inoltre autorità competenti di paesi terzi possono partecipare al programma per la salute se soddisfano i requisiti necessari.

Enti del settore pubblico ed enti non governativi dei paesi summenzionati possono partecipare alle azioni congiunte se ne hanno ricevuto incarico da autorità competenti attraverso una procedura trasparente.

http://ec.europa.eu/chafea/documents/health/hp-factsheets/joint-actions/factsheets-hp-ja_it.pdf

Consumers,
Health And Food
Executive Agency



- European Commission
Consumers, Health and Food Executive Agency
Health Unit

+352 4301 32 814

CHAFEA-HP-JA@ec.europa.eu

<http://ec.europa.eu/chafea/health/actions.html>

- Ministero della salute
Punto Focale Nazionale
Programma Europeo Salute

+39 06 59943173

nfp_eahc@sanita.it

http://http://www.salute.gov.it/portale/p5_1_1.jsp?lingua=italiano&id=195



The screenshot shows a web browser window with the URL http://www.salute.gov.it/portale/p5_1_1.jsp?lingua=italiano&id=195. The page features a header with a navigation menu containing 'La nostra salute' and 'Temi e professioni'. Below the header, the breadcrumb trail reads 'Sei in: Home > Temi e professioni > FAQ > Faq - Joint Actions'. The main heading is 'Faq - Joint Actions'. The page content includes the text 'Ultimo aggiornamento: 5 febbraio 2016' and a list of seven questions, each preceded by a right-pointing chevron symbol (>):

- > 1. Che cosa sono le "Joint Actions"?
- > 2. Chi può partecipare?
- > 3. A quanto ammonta il contributo UE?
- > 4. Quali sono i principi generali di questi finanziamenti?
- > 5. Come partecipare?
- > 6. Chi è stato designato negli anni scorsi?
- > 7. Come è possibile avere ulteriori informazioni?



European
Commission

Thank you for your attention!